Multidrug resistance-associated ABC transporters – too much of one thing, good for nothing

PROCHÁZKOVÁ, Jiřina, Martina LÁNOVÁ and Jiří PACHERNÍK. Multidrug resistance-associated ABC transporters – too much of one thing, good for nothing. Biomolecular concepts. 2012, vol. 3, No 4, p. 319-331. ISSN 1868-5021. Available from: https://dx.doi.org/10.1515/bmc-2012-0006.

Basic information

• Original name: Multidrug resistance-associated ABC transporters – too much of one thing, good for nothing
• Authors: PROCHÁZKOVÁ, Jiřina (203 Czech Republic, guarantor, belonging to the institution), Martina LÁNOVÁ (203 Czech Republic, belonging to the institution) and Jiří PACHERNÍK (203 Czech Republic, belonging to the institution).
• Edition: Biomolecular concepts, 2012, 1868-5021.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30105 Physiology
• Country of publisher: Germany
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• RIV identification code: RIV/00216224:14310/12:00063603
• Organization unit: Faculty of Science
• Doi: http://dx.doi.org/10.1515/bmc-2012-0006
• Keywords in English: ABC transporters; evolution; site mutations
• Tags: AKR, rivok

Abstract

Overexpression of ATP-binding cassette (ABC) transporters in cancer cells results in multidrug resistance (MDR) which leads to unsuccessful chemotherapy. The most important MDR-associated members of ABC superfamily are ABC B1/P-glycoprotein/MDR1, ABC C1/multidrug resistance associated protein 1 (MRP1), and ABC G2/BCRP. This study is not only focused on function, substrates, and localization of these popular proteins but also on other ABC C family members such as ABC C2–6/MRP2-6 and ABC C7/CFTR. Current research is mainly oriented on the cancer-promoting role of these proteins, but important lessons could also be learned from the physiological roles of these proteins or from polymorphisms affecting their function. Thorough knowledge of structure and detailed mechanism of efflux can aid in the discovery of new chemotherapy targets in the future. Although the best way on how to deal with MDR would be to prevent its development, we describe some new promising strategies on how to conquer both inherited and induced MDRs.

Links

• MUNI/A/0975/2009, interní kód MU: Name: Podpora výzkumné činnosti studentů v oblasti fyziologie a imunologie živočichů. (Acronym: VYFIŽ)

Investor: Masaryk University, Category A